David Sans
(He/Him)
New York
As seen in:
The Wall Street Journal,
PR Newswire,
GlobeNewswire,
Capital Press,
BioSpace,
OC Today-Dispatch
Covers:
David started as Sr. Medical Scientist at Novartis during the launch of Glivec® (Imatinib) in Switzerland, Dir. of Market Analytics at Pfizer during the launch or Rebif® (interferon beta-1a for MS)
Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
David Sans’s Biography
Read Full Bio →David Sans, PhD, FAARM MBA
Chief of Corporate Development
David Sans, PhD, FAARM MBA joined Calidi in August of 2022 as Chief Corporate Development bringing with him many years of experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies. David oversees a multi-year, multi-target discovery and development-stage collaborations across therapeutic areas with Pharma spearheading and driving a wi…
David Sans’s Journalist Portfolio
See all 11 portfolio items →
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participat...
Merriman Capital Adds Health Care Investment Banker David Sans, Ph.D. To Financial Entrepreneur P...
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participat...
Interview
See all 20 answers →What was your first job as a journalist?
Wall Street Analyst
Have you ever used a typewriter?
Yes many decades ago.
How is social media changing news?
drastically